一种可控制的自我放大氧化应激策略,用于增强非侵入性声动疗法和协同免疫疗法
Mingting Zhu1, Jiacheng Liu1, Yan Li1
1Key Laboratory of Biomedical Information Engineering of Ministry of Education and Department of Biomedical Engineering, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, PR China.
Biomaterials
|June 24, 2025
概括
这项研究开发了一种新的纳米平台,可以放大氧化压力,用于增强的声动疗 (SDT) 和免疫疗法. 这种方法通过促进免疫反应,显著抑制瘤生长和转移.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 声动力学疗法 (SDT) 和免疫检查点阻断的有效性受到瘤抗氧化防御和免疫抑制瘤微环境 (TME) 的限制.
- 纳米技术可以通过增强声敏剂传递和反应性氧物种 (ROS) 触发的药物释放来改善SDT.
- 需要扩大ROS和与免疫疗法的协同作用的策略.
研究的目的:
- 开发一个pH / ROS双响应纳米平台 (FHPCLNP) 以协同增强SDT和免疫疗法.
- 实施针对瘤组织的"自我放大氧化应激"战略.
- 在4T1乳腺癌模型中研究纳米平台的潜力.
主要方法:
- 制造具有pH / ROS双响应性的FHPCLNP.
- 超声波触发的"药物释放-ROS生成-载体分解"正反循环.
- 在4T1乳腺癌小鼠模型中的评估,评估瘤抑制,免疫细胞激活和转移抑制.
主要成果:
- 在4T1模型中,FHPCLNP建立了积极的反循环,诱导了大量的ROS产生,并在4T1模型中实现了80%以上的局部瘤抑制.
- 该策略显著促进了树突细胞成熟和细胞毒性T淋巴细胞通过免疫细胞死亡透.
- 与FHPCL NPs增强的SDT和抗编程死亡联体1的联合治疗抑制了瘤生长,肺转移,并建立了持久的免疫记忆.
结论:
- 开发的纳米平台通过放大氧化压力为协同瘤治疗提供了一个有希望的战略.
- 这种方法提高了SDT和免疫疗法的疗效,克服了瘤内在的抵抗机制.
- 这项研究强调了综合纳米医学在强效癌症治疗和长期免疫记忆诱导方面的潜力.
更多相关视频
09:07Sonodynamic Therapy for the Treatment of Glioblastoma Multiforme in a Mouse Model Using a Portable Benchtop Focused Ultrasound System
Published on: February 10, 2023
2.6K
07:56Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases
Published on: June 28, 2024
887
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
